Press Room

Event

ASD-HIPROS Learning Lab

Start
Thursday, July 29, 2021 - 00:00
End
Thursday, August 12, 2021 - 00:00
Location: online
Schedule meeting with Hovione ASD-HIPROS Learning Lab | Hovione

Join our exclusive Learning Lab at CPhI North America

“ASD-HIPROS - A new platform for quick and effective 
formulation screening for Amorphous Solid Dispersions by Spray Drying”

 

Join our expert. In just 20 minutes you will learn:

  1. Introduction to Hovione’s new formulation screening platform by Spray Drying
  2. Learn about the advantages of a platform that integrates in silico computational models, formulation, analytical development
  3. Get to know more about Hovione’s extensive expertise in Spray Drying

 

REGISTER NOW

 

Synopsis

The number of drug candidates that present low solubility issues has been increasing over the past years. Amorphous Solid Dispersions (ASDs) are an established platform to address bioavailability challenges of poorly soluble drug candidates, offering many of the advantages of more conventional solid oral dosage forms while providing faster dissolution rates and higher drug concentrations. Suboptimal formulations of poorly soluble compounds may result in clinical failures, ultimately increasing the development timeline and associated costs towards identifying a winning candidate. Register now!

 

Targeted at APIs with poor solubility issues, ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is a methodology able to evaluate if formulations by Spray Drying are viable candidates towards solving poor bioavailability issues. Equipped with a computational platform coupled with state-of-the-art analytical and spray drying technologies, this platform is able to deliver optimal formulations in record time with minimal consumption of API, maximizing the chance of identifying a successful formulation and accelerating development towards clinical supplies.

 

Who should attend:

  1. Formulators
  2. Scientists
  3. Investigators and Research fellows
  4. R&D personnel
  5. Technical services personnel

 

REGISTER NOW

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping
News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Also in Events

See All